RU2015104058A - ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ KRAS И УРОВНЕЙ ЭКСПРЕССИИ RTK - Google Patents
ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ KRAS И УРОВНЕЙ ЭКСПРЕССИИ RTK Download PDFInfo
- Publication number
- RU2015104058A RU2015104058A RU2015104058/15A RU2015104058A RU2015104058A RU 2015104058 A RU2015104058 A RU 2015104058A RU 2015104058/15 A RU2015104058/15 A RU 2015104058/15A RU 2015104058 A RU2015104058 A RU 2015104058A RU 2015104058 A RU2015104058 A RU 2015104058A
- Authority
- RU
- Russia
- Prior art keywords
- inhibitor
- combination
- raf
- tumor
- rtk
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract 38
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 title claims abstract 29
- 101100381978 Mus musculus Braf gene Proteins 0.000 title claims abstract 29
- 206010069755 K-ras gene mutation Diseases 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 claims abstract 23
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims abstract 21
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims abstract 21
- 238000000034 method Methods 0.000 claims abstract 18
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims abstract 11
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims abstract 11
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical group FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims abstract 11
- 229940124647 MEK inhibitor Drugs 0.000 claims abstract 10
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims abstract 10
- 230000001594 aberrant effect Effects 0.000 claims abstract 4
- 229940121647 egfr inhibitor Drugs 0.000 claims abstract 4
- 230000006698 induction Effects 0.000 claims abstract 4
- 206010009944 Colon cancer Diseases 0.000 claims abstract 3
- 239000012824 ERK inhibitor Substances 0.000 claims abstract 3
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims abstract 3
- 208000029742 colonic neoplasm Diseases 0.000 claims abstract 3
- 229960001433 erlotinib Drugs 0.000 claims abstract 3
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims abstract 3
- 230000002195 synergetic effect Effects 0.000 claims abstract 2
- 201000001441 melanoma Diseases 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- G01N2333/91205—Phosphotransferases in general
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23646609P | 2009-08-24 | 2009-08-24 | |
| US61/236,466 | 2009-08-24 | ||
| US30114910P | 2010-02-03 | 2010-02-03 | |
| US61/301,149 | 2010-02-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012111231/15A Division RU2553379C2 (ru) | 2009-08-24 | 2010-08-24 | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015104058A true RU2015104058A (ru) | 2015-06-10 |
Family
ID=43649583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012111231/15A RU2553379C2 (ru) | 2009-08-24 | 2010-08-24 | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
| RU2015104058/15A RU2015104058A (ru) | 2009-08-24 | 2010-08-24 | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ KRAS И УРОВНЕЙ ЭКСПРЕССИИ RTK |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012111231/15A RU2553379C2 (ru) | 2009-08-24 | 2010-08-24 | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ K-ras И УРОВНЕЙ ЭКСПРЕССИИ RTK |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20120214828A1 (enExample) |
| EP (1) | EP2470898A4 (enExample) |
| JP (1) | JP2013502236A (enExample) |
| KR (1) | KR20120050493A (enExample) |
| CN (1) | CN102859355B (enExample) |
| AU (1) | AU2010289794B2 (enExample) |
| BR (1) | BR112012003926A2 (enExample) |
| CA (1) | CA2771369A1 (enExample) |
| IL (2) | IL218099A0 (enExample) |
| IN (1) | IN2012DN01403A (enExample) |
| MX (1) | MX338856B (enExample) |
| MY (1) | MY165154A (enExample) |
| RU (2) | RU2553379C2 (enExample) |
| SG (2) | SG10201402917XA (enExample) |
| WO (1) | WO2011028540A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101945869B (zh) | 2007-12-19 | 2014-06-18 | 癌症研究技术有限公司 | 吡啶并[2,3-b]吡嗪-8-取代化合物及其用途 |
| PH12012501361A1 (en) | 2009-12-31 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Tricyclic compounds for use as kinase inhibitors |
| WO2011092469A1 (en) | 2010-02-01 | 2011-08-04 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| US8709419B2 (en) | 2010-08-17 | 2014-04-29 | Hoffmann-La Roche, Inc. | Combination therapy |
| US9295669B2 (en) | 2010-12-14 | 2016-03-29 | Hoffman La-Roche Inc. | Combination therapy for proliferative disorders |
| WO2012098387A1 (en) | 2011-01-18 | 2012-07-26 | Centro Nacional De Investigaciones Oncológicas (Cnio) | 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors |
| KR20140064971A (ko) * | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| US9408885B2 (en) | 2011-12-01 | 2016-08-09 | Vib Vzw | Combinations of therapeutic agents for treating melanoma |
| US20150017261A1 (en) * | 2012-01-11 | 2015-01-15 | Duke University | Methods of Treating and Preventing Cancer by Disrupting the Binding of Copper in the Map Kinase Pathway |
| US9216170B2 (en) | 2012-03-19 | 2015-12-22 | Hoffmann-La Roche Inc. | Combination therapy for proliferative disorders |
| SG11201500321YA (en) * | 2012-08-07 | 2015-04-29 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
| HK1206605A1 (en) | 2012-08-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Combination therapies for melanoma comprising administering cobimetinib and vemurafinib |
| MX2015005307A (es) * | 2012-10-25 | 2015-07-17 | Glaxosmithkline Llc | Combinacion. |
| EP2786764B1 (en) | 2013-04-01 | 2017-03-08 | Samsung Electronics Co., Ltd. | Combination therapy using anti-c-met antibody and sorafenib |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3805404A1 (en) | 2014-05-13 | 2021-04-14 | Board of Regents, The University of Texas System | Gene mutations and copy number alterations of egfr, kras and met |
| ES2827024T3 (es) * | 2014-12-23 | 2021-05-19 | Dot Therapeutics 1 Inc | Combinación de inhibidores de Raf y de taxanos |
| WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
| WO2017187937A1 (ja) * | 2016-04-28 | 2017-11-02 | デンカ株式会社 | 上皮性細胞成長因子受容体阻害剤に対する癌細胞の耐性を判定する方法 |
| WO2018146253A1 (en) | 2017-02-10 | 2018-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
| US11725185B2 (en) | 2017-12-28 | 2023-08-15 | University Of Houston System | Stem cell culture systems for columnar epithelial stem cells, and uses related thereto |
| MX2020014243A (es) | 2018-06-19 | 2021-05-12 | Biontech Us Inc | Neoantigenos y usos de los mismos. |
| AU2021263742A1 (en) * | 2020-04-27 | 2022-09-22 | Verastem, Inc. | Methods of treating abnormal cell growth |
| US11873296B2 (en) | 2022-06-07 | 2024-01-16 | Verastem, Inc. | Solid forms of a dual RAF/MEK inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3042964A1 (en) * | 2004-06-04 | 2016-07-13 | Genentech, Inc. | Egfr mutations |
| CN101355928B (zh) * | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| WO2007001868A1 (en) * | 2005-06-28 | 2007-01-04 | Genentech, Inc. | Egfr and kras mutations |
| WO2007025044A2 (en) * | 2005-08-24 | 2007-03-01 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators |
| PE20090690A1 (es) * | 2007-03-13 | 2009-06-22 | Amgen Inc | Mutaciones de k-ras y b-raf y terapia con anticuerpos anti-egfr |
-
2010
- 2010-08-24 AU AU2010289794A patent/AU2010289794B2/en not_active Ceased
- 2010-08-24 MY MYPI2012000821A patent/MY165154A/en unknown
- 2010-08-24 RU RU2012111231/15A patent/RU2553379C2/ru not_active IP Right Cessation
- 2010-08-24 JP JP2012526924A patent/JP2013502236A/ja active Pending
- 2010-08-24 BR BR112012003926-1A patent/BR112012003926A2/pt not_active Application Discontinuation
- 2010-08-24 US US13/392,405 patent/US20120214828A1/en not_active Abandoned
- 2010-08-24 WO PCT/US2010/046520 patent/WO2011028540A1/en not_active Ceased
- 2010-08-24 MX MX2012002292A patent/MX338856B/es active IP Right Grant
- 2010-08-24 CN CN201080048007.0A patent/CN102859355B/zh not_active Expired - Fee Related
- 2010-08-24 CA CA2771369A patent/CA2771369A1/en not_active Abandoned
- 2010-08-24 KR KR1020127007529A patent/KR20120050493A/ko not_active Ceased
- 2010-08-24 SG SG10201402917XA patent/SG10201402917XA/en unknown
- 2010-08-24 IN IN1403DEN2012 patent/IN2012DN01403A/en unknown
- 2010-08-24 RU RU2015104058/15A patent/RU2015104058A/ru not_active Application Discontinuation
- 2010-08-24 EP EP10814253A patent/EP2470898A4/en not_active Withdrawn
- 2010-08-24 SG SG2012012860A patent/SG178866A1/en unknown
-
2012
- 2012-02-14 IL IL218099A patent/IL218099A0/en unknown
-
2014
- 2014-05-21 US US14/284,027 patent/US20150164895A1/en not_active Abandoned
- 2014-10-30 IL IL235398A patent/IL235398A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20120050493A (ko) | 2012-05-18 |
| IL218099A0 (en) | 2012-04-30 |
| EP2470898A4 (en) | 2013-03-13 |
| MY165154A (en) | 2018-02-28 |
| US20150164895A1 (en) | 2015-06-18 |
| SG10201402917XA (en) | 2014-08-28 |
| RU2553379C2 (ru) | 2015-06-10 |
| WO2011028540A1 (en) | 2011-03-10 |
| MX2012002292A (es) | 2012-03-19 |
| IN2012DN01403A (enExample) | 2015-06-05 |
| HK1175248A1 (zh) | 2013-06-28 |
| CN102859355A (zh) | 2013-01-02 |
| AU2010289794A1 (en) | 2012-04-05 |
| IL235398A0 (en) | 2014-12-31 |
| EP2470898A1 (en) | 2012-07-04 |
| JP2013502236A (ja) | 2013-01-24 |
| BR112012003926A2 (pt) | 2020-08-11 |
| CN102859355B (zh) | 2015-10-07 |
| AU2010289794B2 (en) | 2014-10-02 |
| CA2771369A1 (en) | 2011-03-10 |
| SG178866A1 (en) | 2012-04-27 |
| RU2012111231A (ru) | 2013-10-10 |
| US20120214828A1 (en) | 2012-08-23 |
| MX338856B (es) | 2016-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015104058A (ru) | ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ KRAS И УРОВНЕЙ ЭКСПРЕССИИ RTK | |
| Brustugun et al. | BRAF-mutations in non-small cell lung cancer | |
| Huse et al. | The evolving role of molecular markers in the diagnosis and management of diffuse glioma | |
| PH12019501116A1 (en) | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 | |
| EA201390550A1 (ru) | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях | |
| JP2015505959A5 (enExample) | ||
| AR095699A1 (es) | Terapia de combinación | |
| WO2005017493A3 (en) | Biomarkers in cancer | |
| MA31150B1 (fr) | Antagonistes spécifiques de vegf pour thérapie par adjuvant et néoadjuvant et traitement de tumeurs de premier stade | |
| RU2013146242A (ru) | Fgfr и его лиганды в качестве биомаркеров рака молочной железы у hr-положительных индивидуумов | |
| EA201190042A1 (ru) | Имидазопиразиновые ингибиторы тирозинкиназы syk | |
| Ebos et al. | Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy | |
| NZ627443A (en) | Biological markers for identifying patients for treatment with vegf antagonists | |
| MX2019005443A (es) | Combinacion de un inhibidor de brd4 y un antifolato para la terapia del cancer. | |
| EA201390740A1 (ru) | Способ лечения с использованием ингибитора braf | |
| Li et al. | Prognostic role of elevated preoperative systemic inflammatory markers in localized soft tissue sarcoma | |
| MX2020012548A (es) | Métodos para el tratamiento de mieloma múltiple y uso de biomarcadores para 4-(4-(4-(((2-(2,6-dioxopiperidin-3-il)-1-oxoiso indolin-4-il)oxi)metil)bencil)piperazin-1- il)-3-fluorobenzonitril o. | |
| Yeung et al. | K‐Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines | |
| BR112015012331A2 (pt) | autenticação social | |
| CY1111356T1 (el) | Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl | |
| Ogrunc | Reactive oxygen species: the good, the bad, and the enigma | |
| Li et al. | Comparing patient-derived xenograft and computational response prediction for targeted therapy in patients of early-stage large cell lung cancer | |
| RU2017101809A (ru) | Способы лечения рака и профилактики устойчивости рака к лекарственному средству | |
| Ogawa | Splicing factor mutations in AML | |
| MX2022003197A (es) | Perfilado espacial cuantitativo para terapia con antagonistas de la proteina del gen de activacion de linfocitos 3 (lag-3). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20180207 |